All major technology advances in the world of radiology and imaging are unveiled or highlighted at the Radiological Society of North America (RSNA) annual meeting in Chicago.

Fujifilm Medical Systems U.S.A. Inc. will show several new technologies at the 100th annual meeting of the Radiological Society of North America (RSNA) in Chicago.

Toshiba America Medical Systems Inc.’s Kalare R&F digital X-ray system with flat panel detector (FPD) has received U.S. Food and Drug Administration (FDA) clearance.

Ascendian Healthcare Consulting, a national healthcare IT consultancy, partners with Medical Imaging expert Mike Cannavo to deliver the PACS Check Up and PACS Sanity Check to healthcare providers seeking evaluation and optimization of existing radiology imaging 

American Shared Hospital Services announced that the Centers for Medicare and Medicaid Services (CMS) has posted its final Medicare hospital outpatient prospective payment rates for calendar year 2015. The rates for Gamma Knife and proton therapy remained as proposed earlier this year.

Siemens Healthcare announces the availability of the Acuson X600 – a new ultrasound system with advanced technologies migrated from premium Siemens systems and workflow efficiencies for clinical applications in general imaging, obstetrics and gynecology and cardiology.

Elekta's Clarity 4-D prostate monitoring system can now automatically interrupt, or "gate," the radiation beam when it detects that the prostate has moved out of position. Clarity 4-D Monitoring software has enabled doctors to continuously visualize the prostate's precise location during radiation therapy. U.S. Food and Drug Administration (FDA) 510(k) clearance for Clarity to be used with Elekta's Response gating interface will give United States physicians the potential to further safeguard the patient's normal tissues from overexposure to radiation during prostate radiotherapy. The feature is available as an option with Elekta's advanced Versa HD radiation therapy treatment system.

Medicare Costs Analysis Indicates Need for Decreasing Use of Biopsies as Diagnosis Tool for Lung Cancer

Biopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago Medicine.

The Ohio State’s Comprehensive Cancer Center has developed a treatment that allows patients to lie on their stomachs while the breast tissue falls away from the chest wall, allowing the radiation to target the cancer.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now